SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.

Summary of New Transactions:

$1.15 billion 5-year senior secured Term Loan A, which replaces the Company's previous Term Loan A entered into in 2022

$100 million delayed draw Term Loan A (undrawn at close)

$1.45 billion 7-year senior secured Term Loan B

$700 million revolving credit facil

See Full Page